Harvard Bioscience, Inc. (HBIO)
Market Cap | 180.11M |
Revenue (ttm) | 112.25M |
Net Income (ttm) | -3.42M |
Shares Out | 43.40M |
EPS (ttm) | -0.08 |
PE Ratio | n/a |
Forward PE | 18.22 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 413,782 |
Open | 4.060 |
Previous Close | 4.050 |
Day's Range | 3.840 - 4.300 |
52-Week Range | 2.850 - 6.290 |
Beta | 1.43 |
Analysts | Buy |
Price Target | 7.00 (+68.68%) |
Earnings Date | Mar 7, 2024 |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellula... [Read more]
Financial Performance
In 2023, HBIO's revenue was $112.25 million, a decrease of -0.96% compared to the previous year's $113.34 million. Losses were -$3.42 million, -64.11% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for HBIO stock is "Buy." The 12-month stock price forecast is $7.0, which is an increase of 68.68% from the latest price.
News
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti's Small Cap Conference and KeyBanc's Life Sciences & MedTech Conference
HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at th...
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
HOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023.
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics Solutions for CROs, pharma and biotechs improve throughput and efficiency and...
Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March...
Harvard Bioscience to Present at Benchmark Company's Discovery One-On-One Investor Conference on December 7, 2023
HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Con...
Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwe...
Harvard Bioscience Announces Third Quarter 2023 Financial Results
HOLLISTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2023.
Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023
HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (S...
Harvard Bioscience Schedules Third Quarter 2023 Earnings Conference Call for November 7, 2023 at 8:00 AM ET
HOLLISTON, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2023 before the market opens on Nove...
Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)
Harvard Bioscience Announces Second Quarter 2023 Financial Results
HOLLISTON, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2023.
Harvard Bioscience to Present at Sidoti Virtual Investor Conference on August 16, 2023
HOLLISTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Sidoti ...
Harvard Bioscience Schedules Second Quarter 2023 Earnings Conference Call for August 8, 2023 at 8:00 AM ET
HOLLISTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2023 before the market opens on August 8,...
Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes
HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced that it is set to join the Russell 2000® and Russell 3000 Indexes, according...
Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer an...
Harvard Bioscience to Present at Sidoti Micro Cap Virtual Conference May 10th, 2023
HOLLISTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings...
Harvard Bioscience Announces First Quarter 2023 Financial Results
HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2023.
Harvard Bioscience Announces Initial Order for Integrated Animal Behavior Monitoring System
Designed to meet the pre-clinical testing needs of CROs, pharma and research laboratories Designed to meet the pre-clinical testing needs of CROs, pharma and research laboratories
Harvard Bioscience Schedules First Quarter 2023 Earnings Conference Call for April 25, 2023 at 9:00 AM ET
HOLLISTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2023 before the market opens on April 2...
Harvard Bioscience to Present at Sidoti Investor Conference March 22-23, 2023
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetin...
Harvard Bioscience to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetin...
Harvard Bioscience Announces Fourth Quarter 2022 Financial Results
HOLLISTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022.
Harvard Bioscience Schedules Fourth Quarter 2022 Earnings Conference Call for March 9, 2023 at 8:00 AM ET
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2022 before the market opens on Ma...
Harvard Bioscience Announces CFO Transition
HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company's chief financial officer and ...
Harvard Bioscience Announces Third Quarter 2022 Financial Results
“Fighting through challenging times while building the company and new technologies for the future.” “Fighting through challenging times while building the company and new technologies for the future...